The impact of SARS-CoV² has everyone trying to manage patient care with a sharp eye on resources. With a focus on OR efficiency, minimizing prolonged stays and reducing readmissions and preventable complications is vital to patient flow and facility economics. As you look for solutions that provide extended value, it may be time to consider how PREVENA™ Therapy protects you, your patients, and your practice well beyond the incision site.
PREVENA™ Therapy is the first and only medical device indicated by FDA to help reduce superficial surgical site infections in high-risk patients in Class I and II wounds*
PREVENA™ Therapy is uniquely engineered to empower incision management that works to protect patients, surgeons, staff, practices, and hospitals during the SARS-CoV-2 pandemic.